Humacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Consensus Price Target from Analysts
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has received a consensus rating of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the […]
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has received a consensus rating of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the […]
